Due to recent regulatory restrictions in China and intensified enforcement actions affecting pharmaceutical raw material manufacturers, the global pharmaceutical industry is currently experiencing significant difficulties in sourcing pharmaceutical-grade ingredients for hormone-based formulations.

As a result, stock levels of many hormone-related products have been depleted worldwide, while new raw material batches remain limited or unavailable across multiple markets.